Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Mushrooms for PTSD
NCT07275970Phase 1Active, not recruiting
- Sponsor
- Scottsdale Research Institute
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by Scottsdale Research Institute. Primary endpoints: Number/Incidence of Adverse Events and Serious Adverse Events at 3 months and Number/Incidence of Mental and Psychotic Adverse Events at 3 months. Started Mar 2026; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07275970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275970.